Reviva Pharmaceuticals Holdings, Inc. - RVPH STOCK NEWS

Reviva Pharmaceuticals (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, Ph.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The conference will be virtual, allowing attendees to join remotely. An on-demand presentation will be available starting September 13 at 7am ET for 90 days. Reviva focuses on developing therapies for unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases, with key drug candidates RP5063 and RP1208.

Reviva Pharmaceuticals (NASDAQ: RVPH) closed a successful public offering, raising $34.5 million in gross proceeds, enhancing its liquidity for future clinical trials. The company plans to initiate a pivotal Phase 3 trial for its drug brilaroxazine in treating schizophrenia in Q4 2021. As of June 30, 2021, Reviva maintained a cash reserve of $35.8 million, compared to just $0.2 million a year earlier. Despite reporting a net loss of $2.6 million for Q2 2021, the funds secured will facilitate upcoming drug development and operations.

Reviva Pharmaceuticals (NASDAQ: RVPH) has been added to the Russell Microcap® Index as of June 28, 2021, following the annual reconstitution of the Russell U.S. Indexes. This inclusion, which identifies the largest U.S. stocks based on market capitalization, is expected to enhance Reviva's visibility among investors, particularly as the company plans to initiate a Phase 3 trial for its schizophrenia treatment later this year. The Russell Indexes are widely used by investment managers and benchmark over $9 trillion in assets.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has priced an upsized public offering of 8,000,000 shares of common stock at $3.75 each, along with investor warrants for an additional 6,000,000 shares. Gross proceeds are expected to total approximately $30 million, aimed at advancing the clinical development of brilaroxazine for treating schizophrenia and for general corporate purposes. The offering is set to close on June 1, 2021. Maxim Group LLC is the lead underwriter, with a 45-day option granted for underwriters to purchase additional shares.

Reviva Pharmaceuticals (NASDAQ: RVPH) announced positive results from its Phase 2 clinical trial for RP5063 (brilaroxazine) aimed at treating Acute Schizophrenia in 234 patients. The trial successfully met its primary endpoint by demonstrating a significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score by 20 points compared to placebo. Importantly, the drug showed improved safety with no metabolic or endocrine side effects. Reviva is optimistic about obtaining a 'Superior Safety' label claim from the FDA pending results from a pivotal Phase 3 study.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has successfully closed its merger with Tenzing Acquisition Corp, marking its public listing. The company reported a 2020 net loss of $3.8 million, compared to $847,000 the previous year. Reviva plans to initiate a pivotal Phase 3 trial for its lead asset, brilaroxazine, targeting schizophrenia. The trial is expected to start in mid-2021, contingent on achieving fundraising goals. As of December 31, 2020, Reviva had $8.8 million in cash, allowing it to cover operating expenses through 2021.

Reviva Pharmaceuticals (NASDAQ: RVPH) announced its participation in the Maxim Group Inaugural Emerging Growth Virtual Conference scheduled for March 17-19, 2021. The company will feature a pre-recorded presentation and engage in a live fireside chat on March 17 from 4:30 – 5:00 pm ET. Webcasts will be accessible via the conference portal and Reviva's investor website. Reviva focuses on developing therapies for unmet medical needs in CNS, cardiovascular, and metabolic diseases, with pipeline candidates RP5063 and RP1208.

Reviva Pharmaceuticals (NASDAQ: RVPH) announced its participation at the H.C. Wainwright Global Life Sciences Conference, held virtually on March 9-10, 2021. Attendees can access a pre-recorded presentation on-demand starting March 9 at 7 a.m. ET. Reviva focuses on developing therapies for the central nervous system, cardiovascular, metabolic, and inflammatory diseases, with its lead candidate, RP5063 (brilaroxazine), targeting schizophrenia and other mental health disorders. The company is committed to addressing unmet medical needs amidst industry challenges.

Reviva Pharmaceuticals Holdings, Inc. has successfully completed its merger with Tenzing Acquisition Corp., transitioning to the ticker symbols RVPH for common stock and RVPHW for warrants effective December 15, 2020. This combination enables Reviva to access public markets and drive clinical development of its lead drug, Brilaroxazine (RP5063), which is positioned to address unmet needs in CNS and respiratory diseases. The partnership aims to enhance shareholder value and expedite treatment advancements, particularly for schizophrenia and pulmonary hypertension.